Cargando…

Bimodality treatment of patients with pelvic adenoid cystic carcinoma with photon intensity-modulated radiotherapy plus carbon ion boost: a case series

BACKGROUND: Treatment of patients with pelvic adenoid cystic carcinoma (ACC) remains a challenge owing to the rarity of the disease, the lack of data, and the relative radioresistance of these tumors. CASE REPORTS: This case series presents the results of three patients with recurrent or inoperable...

Descripción completa

Detalles Bibliográficos
Autores principales: Bernhardt, Denise, Sterzing, Florian, Adeberg, Sebastian, Herfarth, Klaus, Katayama, Sonja, Foerster, Robert, Hoerner-Rieber, Juliane, König, Laila, Debus, Juergen, Rieken, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5875408/
https://www.ncbi.nlm.nih.gov/pubmed/29618938
http://dx.doi.org/10.2147/CMAR.S148395
Descripción
Sumario:BACKGROUND: Treatment of patients with pelvic adenoid cystic carcinoma (ACC) remains a challenge owing to the rarity of the disease, the lack of data, and the relative radioresistance of these tumors. CASE REPORTS: This case series presents the results of three patients with recurrent or inoperable pelvic ACC treated with intensity-modulated radiotherapy (IMRT) plus carbon ion (C12) boost. Patients received C12 therapy at a dose of 3 Gray equivalents (GyE) (relative biological effectiveness [RBE]) per fraction up to 24 GyE RBE, followed by 50 GyE of photon IMRT in 25 fractions. CONCLUSION: IMRT plus C12 ion boost as a definitive or adjuvant treatment for pelvic ACCs seems to be a promising therapeutic option. No unexpected toxicity was detected and the observed toxicity remained consistently low. The initial treatment response is promising and similar to that experienced for head and neck ACCs.